Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Jul 30, 2008
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Following percutaneous coronary intervention with bare metal stents, the rate of major adverse cardiovascular events including death, myocardial infarction and target lesion revascularization is high ranging between 20 and 25%.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\>18 years old
- • Scheduled for PCI
- • Clinical evidence of ischemic heart disease and/or abnormal functional study
- • New coronary artery lesion \>50%
- • treatment with bare metal stent planned
- • Informed consent explained, red, understood and signed by the patient
- Exclusion Criteria:
- • Pregnancy, birth or lactation period \<6 months ago
- • Women of childbearing age who do not intend to use accepted anticonceptive measures or who wish to get pregnant
- • Left ventricular ejection fraction \<30%
- • Acute coronary syndrome (ST-elevation or not) in the past month
- • Planned drug eluting stent implantation
- • Lesion in arterial or venous bypass or anastomosis with coronary
- • Severe renal insufficiency (creatinine clearance \<30 mL/')
- • Severe hepatic insufficiency
- • Systemic inflammatory pathology of any kind
- • Hematologic or other malignancy, prior radio- or chemotherapy
- • Use of corticosteroïds or immune suppression therapy
- • Contrast allergy
- • Life expectancy \<1 year
- • Participation in other clinical study which has not ended yet
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Trial Officials
Franck PAGANELLI, MD
Principal Investigator
Assistance Publique des Hopitaux de Marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials